3 citations
,
January 2025 in “Journal of Natural Products” Calancardin B may help reduce inflammation in immune cells.
1 citations
,
January 2021 in “Journal of clinical and diagnostic research” Using Calcipotriol with Clobetasol is more effective for treating Alopecia Areata than using Clobetasol alone.
January 2024 in “Journal der Deutschen Dermatologischen Gesellschaft” Non-biologic immunosuppressive drugs are crucial for treating autoimmune and chronic inflammatory skin diseases.
5 citations
,
April 2025 in “Journal of the European Academy of Dermatology and Venereology” Control inflammation and prevent further hair loss in folliculitis decalvans using medications and therapies.
10 citations
,
January 2014 in “Journal of Pharmaceutical Sciences” Balancing lipophilicity and solubility is key for effective and safe ketorolac prodrugs.
May 2017 in “Journal of the American Academy of Dermatology”
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
24 citations
,
May 2010 in “Veterinary dermatology” Oral ciclosporin A and topical treatments both reduce hair loss and scaling in dogs with sebaceous adenitis, but using both together is most effective.
2 citations
,
September 2021 in “Curēus” Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
June 2014 in “Dermatology Times E-News” An arthritis drug helped a person with severe hair loss regrow their hair.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
1 citations
,
March 2023 in “Colloids and surfaces. B, Biointerfaces” A new wound dressing with p-Coumaric acid helps heal diabetic wounds faster by reducing inflammation and promoting skin repair.
December 2023 in “Majalah Kedokteran Gigi Indonesia” Cinnamaldehyde helps bone healing initially but may slow healing later unless combined with DHT treatment.
May 2025 in “Pakistan Armed Forces Medical Journal” Dithranol is more effective than Tacrolimus for hair regrowth in alopecia areata.
March 2023 in “Oxford University Press eBooks” November 2020 in “Universal Journal of Pharmaceutical Research” Tacrolimus is a better option than cyclosporine due to fewer side effects.
March 2002 in “Clin-Alert” In 2002, various drugs caused serious side effects, including vitamin B12 deficiency, heart issues, blindness, hypersexuality, allergic reactions, blood clotting problems, pupil dilation, capillary leak syndrome, muscle breakdown, hepatitis, skin reactions, and lupus.
4 citations
,
January 2022 in “Dermatologic Therapy” Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
1 citations
,
September 2024 in “Life” Combining fractionated CO2 laser with tacrolimus may help treat chronic alopecia areata.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
1 citations
,
January 2018 in “Side effects of drugs annual” Diuretics can cause serious side effects and should be used carefully.
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
31 citations
,
September 2014 in “International Journal of Dermatology” Anthralin is effective for psoriasis and alopecia with minimal systemic side effects but can irritate the skin.
December 2024 in “PubMed” Cyclosporine effectively treated a woman's stubborn skin condition.
May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
1 citations
,
January 2024 in “Arab Board Medical Journal” Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
February 2023 in “Reactions Weekly”